Nepafenac
Nepafenac: 2 brands, 0 generics; first approved Aug 19, 2005; on patent until Jan 31, 2027.
Protected until Jan 31, 2027 (earliest listed patent expiry).
Brand (NDA) products
Patent & exclusivity timeline
Listed patents
| Patent | Expires | In | Type |
|---|---|---|---|
| 7834059 | in 3 mo | U-1095 | |
| 9662398 | in 4 yr 2 mo | Product | |
| 8921337 | in 5 yr 6 mo | Product |
Approval history
Approvals span 2005–2012 across 2 FDA applications.
Nepafenac: frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.
Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Related FDA reference tools
- FDA Purple BookLicensed biologics, biosimilars, interchangeables, BLA records, and exclusivity dates.
- FDA BiosimilarsFDA-approved biosimilars and interchangeable biosimilars, by reference product.
- 510(k) Predicate DatabaseSearch FDA 510(k) clearances and map predicate-device lineage.
- FDA 483 DatabaseFDA Form 483 observations and inspection records by firm, date, and citation.
Assyro Intelligence
Ask anything about Nepafenac
Cited answers from FDA, EMA, Health Canada, PubMed and ClinicalTrials.gov, in seconds. Free, no sign-up.
Evaluating for a team? Book a demo